Ablynx, a Sanofi company, is a Belgian biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments.
Today, the Company has approximately 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. (status August 2018)
Running 1 Phase III study and 4 Phase II studies
>40 in early development
Unique and powerful
technology platform
>500 patents
granted and pending
6 pharma partners
across the globe
>450 employees
20 nationalities